Reviews

This collection gathers reviews (critical assessments of books, articles, papers, etc.) written by UAB teachers and researchers or published in the university journals.

Usage statistics Most popular
Latest additions:
2024-02-21
14:04
22 p, 4.4 MB Towards a druggable epitranscriptome : Compounds that target RNA modifications in cancer / Berdasco, M. (Institut d'Investigació Biomèdica de Bellvitge) ; Esteller, M. (Institució Catalana de Recerca i Estudis Avançats)
Epitranscriptomics is an exciting emerging area that studies biochemical modifications of RNA. The field has been opened up by the technical efforts of the last decade to characterize and quantify RNA modifications, and this has led to a map of post-transcriptional RNA marks in normal cell fate and development. [...]
2022 - 10.1111/bph.15604
British Journal of Pharmacology, Vol. 179 Núm. 12 (june 2022) , p. 2868-2889  
2024-02-21
14:04
8 p, 1.2 MB AXL - a new player in resistance to HER2 blockade / Adam-Artigues, Anna (INCLIVA Biomedical Research Institute) ; Arenas, Enrique J. (Center for Biomedical Network Research on Cancer) ; Arribas, Joaquin (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Prat, Aleix (SOLTI Breast Cancer Research Group) ; Cejalvo, Juan Miguel (Vall d'Hebron Institut d'Oncologia)
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. [...]
2023 - 10.1016/j.ctrv.2023.102639
Cancer Treatment Reviews, Vol. 121 (december 2023) , p. 102639  
2024-02-21
14:04
42 p, 1.8 MB Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics / Janin, Maxime (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Most of the cancer-associated mortality and morbidity can be attributed to metastasis. The role of epigenetic and epitranscriptomic alterations in cancer origin and progression has been extensively demonstrated during the last years. [...]
2023 - 10.1007/s10555-023-10120-3
Cancer and Metastasis Reviews, Vol. 42 Núm. 4 (december 2023) , p. 1071-1112  
2024-02-21
14:04
49 p, 3.2 MB Cancer epigenetics in clinical practice / Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteller, Manel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Cancer development is driven by the accumulation of alterations affecting the structure and function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic alterations contribute to the acquisition of hallmark tumor capabilities by regulating gene expression programs that promote tumorigenesis. [...]
2023 - 10.3322/caac.21765
CA Cancer Journal for Clinicians, Vol. 73 Núm. 4 (2023) , p. 376-424  
2024-02-20
08:38
Multidisciplinary management of head and neck cancer : First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1) / Mañós, M. (Hospital Universitari de Bellvitge) ; Giralt, J. (Hospital Universitario de la Vall Hebrón) ; Rueda, A. (Hospital Costa del Sol (Marbella)) ; Cabrera, J. (Hospital Infanta Cristina) ; Martinez-Trufero, J. (Hospital Universitario Miguel Servet (Saragossa)) ; Marruecos, J. (ICO Girona) ; Lopez-Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ; Rodrigo, J.P. (Hospital Universitario Central de Asturias) ; Castelo, B. (Hospital Universitario La Paz (Madrid)) ; Martínez-Galán, J. (Hospital Universitario Virgen de las Nieves (Granada)) ; Arias, F. (Complejo Hospitalario de Navarra) ; Chaves, M. (Hospital de Valme) ; Herranz, J.J. (Complejo Hospitalario Universitario de A Coruña) ; Arrazubi, V. (Hospital de Basurto (Bilbao, Biscaia)) ; Baste, N. (Hospital Universitario de la Vall Hebrón) ; Castro, A. (Hospital Universitario La Paz (Madrid)) ; Mesía, R. (ICO L'Hospitalet de Llobregat) ; Universitat Autònoma de Barcelona
Head and neck cancer is one of the most frequent malignances worldwide. Despite the site-specific multimodality therapy, up to half of the patients will develop recurrence. Treatment selection based on a multidisciplinary tumor board represents the cornerstone of head and neck cancer, as it is essential for achieving the best results, not only in terms of outcome, but also in terms of organ-function preservation and quality of life. [...]
2017 - 10.1016/j.oraloncology.2017.04.004
Oral Oncology, Vol. 70 (july 2017) , p. 58-64  
2024-02-19
16:21
23 p, 7.8 MB Deep learning applications in single-cell genomics and transcriptomics data analysis / Erfanian, Nafiseh (Birjand University of Medical Sciences, Birjand, Iran) ; Heydari, A.Ali (University of California, USA) ; Feriz, Adib Miraki (Birjand University of Medical Sciences, Birjand, Iran) ; Iañez, Pablo (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Derakhshani, Afshin (University of Calgary, Canada) ; Ghasemigol, Mohammad (University of North Dakota, USA) ; Farahpour, Mohsen (University of Birjand, Iran) ; Razavi, Seyyed Mohammad (University of Birjand, Iran) ; Nasseri, Saeed (Birjand University of Medical Sciences, Iran) ; Safarpour, Hossein (Birjand University of Medical Sciences, Iran) ; Sahebkar, Amirhossein (Mashhad University of Medical Sciences, Mashhad, Iran)
Traditional bulk sequencing methods are limited to measuring the average signal in a group of cells, potentially masking heterogeneity, and rare populations. The single-cell resolution, however, enhances our understanding of complex biological systems and diseases, such as cancer, the immune system, and chronic diseases. [...]
2023 - 10.1016/j.biopha.2023.115077
Biomedicine & pharmacotherapy, Vol. 165 (september 2023)  
2024-02-16
11:04
14 p, 563.4 KB Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors : The necessity of repeated molecular analysis / González-Larriba, J.L. (Hospital Universitario San Carlos) ; Lázaro-Quintela, M. (Complejo Hospitalario Universitario de Vigo) ; Cobo, M. (Hospital Universitario de Málaga) ; Dómine, M. (Hospital Universitario Fundación Jiménez Díaz) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; García-Campelo, R. (Hospital Universitario de A Coruña) ; Universitat Autònoma de Barcelona
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene. [...]
2017 - 10.21037/tlcr.2017.10.03
Translational Lung Cancer Research, Vol. 6 (january 2017) , p. S21-S34  
2024-02-12
08:07
9 p, 1.6 MB Multilayered and digitally structured presentation formats of trustworthy recommendations : A combined survey and randomised trial / Brandt, Linn (University of Oslo) ; Vandvik, Per Olav (University of Oslo) ; Alonso-Coello, Pablo (Institut d'Investigació Biomèdica Sant Pau) ; Akl, Elie A. (American University of Beirut) ; Thornton, Judith (National Institute for Health and Care Excellence) ; Rigau, David (Institut d'Investigació Biomèdica Sant Pau) ; Adams, Katie (National Institute for Health and Care Excellence) ; O'connor, Paul (National Institute for Health and Care Excellence) ; Guyatt, Gordon (McMaster University (Canadà)) ; Kristiansen, Anette (University of Oslo) ; Universitat Autònoma de Barcelona
To investigate practicing physicians' preferences, perceived usefulness and understanding of a new multilayered guideline presentation format - compared to a standard format - as well as conceptual understanding of trustworthy guideline concepts. [...]
2017 - 10.1136/bmjopen-2016-011569
BMJ open, Vol. 7 Núm. 2 (january 2017) , p. e011569  
2024-02-12
08:07
19 p, 1.6 MB Strategies to design clinical studies to identify predictive biomarkers in cancer research / Perez-Gracia, Jose Luis (Clínica Universidad de Navarra) ; Sanmamed, Miguel F. (Yale University School of Medicine) ; Bosch, Ana (Lund University) ; Patiño-Garcia, Ana (Clinica Universidad de Navarra) ; Schalper, Kurt A. (Yale School of Medicine) ; Segura, Victor (Universidad de Navarra) ; Bellmunt, Joaquim (Dana-Farber Cancer Institute and Harvard Medical School) ; Tabernero, Josep (Hospital Universitari Vall d'Hebron) ; Sweeney, Christopher J. (Dana-Farber Cancer Institute and Harvard Medical School) ; Choueiri, Toni K. (Dana-Farber Cancer Institute and Harvard Medical School) ; Martín Jiménez, Miguel (Instituto de Investigación Sanitaria Gregorio Marañón) ; Fusco, Juan Pablo (Clinica Universidad de Navarra) ; Rodriguez-Ruiz, Maria Esperanza (Universidad de Navarra) ; Calvo, Alfonso (Universidad de Navarra) ; Prior, Celia (Universidad de Navarra) ; Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ; Pio, Ruben (Universidad de Navarra) ; Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ; Gonzalez Hernandez, Alvaro (Clinica Universidad de Navarra) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Piulats, Jose María (Institut Català d'Oncologia) ; Gurpide, Alfonso (Universidad de Navarra) ; Andueza, Mapi (Clinica Universidad de Navarra) ; de Velasco, Guillermo (Dana-Farber Cancer Institute and Harvard Medical School) ; Pazo, Roberto (Hospital Universitario Miguel Servet) ; Grande, Enrique (Hospital Universitario Ramón y Cajal) ; Nicolas, Pilar (Universidad del País Vasco) ; Abad-Santos, Francisco (Instituto de Investigación Sanitaria la Princesa (IP)) ; Garcia-Donas, Jesus (Centro Integral Oncológico HM Clara Campal) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Pajares, María J. (Universidad de Navarra) ; Suárez, Cristina (Hospital Universitari Vall d'Hebron) ; Colomer, Ramon (Hospital Universitario de la Princesa) ; Montuenga, Luis M. (Universidad de Navarra) ; Melero, Ignacio (Universidad de Navarra) ; Universitat Autònoma de Barcelona
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. [...]
2017 - 10.1016/j.ctrv.2016.12.005
Cancer Treatment Reviews, Vol. 53 (january 2017) , p. 79-97  
2024-02-09
09:10
52 p, 705.6 KB Role of Amyloid-β and Tau Proteins in Alzheimer's Disease : Confuting the Amyloid Cascade / Gulisano, W. (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ; Maugeri, Daniele (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ; Baltrons Soler, Ma. Antonia (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ; Fà, Mauro (Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Department of Medicine. Columbia University) ; Amato, Arianna (Department of Anaesthesiology. Università Cattolica Del Sacro Cuore) ; Palmeri, Agostino (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ; D'Adamio, Luciano (Department of Pharmacology. Physiology and Neuroscience. Rutgers University) ; Grassi, Claudio (Institute of Human Physiology. Università Cattolica Del Sacro Cuore) ; Devanand, D.P. (Department of Psychiatry. Columbia University. College of Phys. and Surg.) ; Honig, Lawrence S. (Department of Neurology. Columbia University. College of Phys. and Surg.) ; Puzzo, Daniela (Department of Biomedical and Biotechnological Sciences. Section of Physiology. University of Catania) ; Arancio, Ottavio (Taub Institute for Research on Alzheimer's Disease and the Aging Brain. Department of Medicine. Columbia University)
The "Amyloid Cascade Hypothesis" has dominated the Alzheimer's disease (AD) field in the last 25 years. It posits that the increase of amyloid-β (Aβ) is the key event in AD that triggers tau pathology followed by neuronal death and eventually, the disease. [...]
2018 - 10.3233/JAD-179935
Journal of Alzheimer's disease, Vol. 64 Núm. s1 (2018) , p. S611-S631